

# Alabama Medicaid Agency



501 Dexter Avenue  
P.O. Box 5624  
Montgomery, Alabama 36103-5624  
www.medicaid.alabama.gov  
e-mail: almedicaid@medicaid.alabama.gov

ROBERT BENTLEY  
Governor

Telecommunication for the Deaf: 1-800-253-0799  
334-242-5000 1-800-362-1504

STEPHANIE MCGEE AZAR  
Acting Commissioner

September 18, 2015

Dear Pharmaceutical Manufacturer:

This correspondence is to provide you with formal written notification of an upcoming meeting of the Alabama Medicaid Pharmacy & Therapeutics (P&T) Committee, to be held on **Wednesday, November 4, 2015**. This meeting may involve review of one or more of your company's drug products. Please note: this meeting will be held in the Commissioner's Board Room at the Alabama Medicaid Building located in Montgomery, Alabama and will begin at 9:00 a.m. All meetings of this Committee are open to the public.

The following is a list of drug classes for re-review at this meeting:

## Drug Class RE-REVIEWS

1. Inhaled Antimuscarinics – AHFS 120808
2. Respiratory  $\beta$ -adrenergic agonists – AHFS 121208
3. Leukotriene Modifiers – AHFS 481024
4. Inhaled Mast-cell Stabilizers – AHFS 481032
5. Respiratory Agents-Corticosteroids – AHFS 481008
6. Respiratory Smooth Muscle Relaxants – AHFS 861600
7. Intranasal Corticosteroids – AHFS 520808
8. Eye, Ear, Nose and Throat Preparations-Antiallergic Agents – AHFS 520200
9. Eye, Ear, Nose and Throat Preparations -Antibacterials – AHFS 520404
10. Eye, Ear, Nose and Throat Preparations -Vasoconstrictors – AHFS 523200
11. Androgens – AHFS 680800

## New Drug REVIEWS

1. Afrezza<sup>®</sup> (Insulins) – AHFS 682008
2. Jardiance<sup>®</sup> (Sodium-glucose Cotransporter 2 (SGLT2) Inhibitor) – AHFS 682018

While we understand there is a level of coordination between members of the manufacturing industry and a provider through the normal course of business, Alabama Medicaid asks manufacturers to respect P&T Committee members' commitment to the State of Alabama by following the procedures available through the P&T policy. Also, as outlined in the P&T Committee Statement of Integrity, Committee members agree not to have ex parte contacts or discussions with manufacturers or representatives whose drugs are presented for review. This is specifically regarding drugs to be reviewed in an upcoming Medicaid P&T meeting.

As you may be aware, manufacturers whose products are scheduled for review are allowed the opportunity to provide written clinical comments for distribution to the Medicaid P&T Committee members prior to the meeting. For products slated for P&T Committee review, manufacturers are also allowed the opportunity to make brief (no more than 5 minutes) oral summary presentations of their products' clinical data to the Medicaid P&T Committee on the day of the meeting. At the initiation of the 5 minute presentation, the speaker will be required to state any financial interest in or other relationship with the manufacturer of any product(s) the speaker intends to discuss. Speakers may not solicit questions from P&T members during the oral presentation. All questions from Medicaid P&T Committee members regarding specific products and/or AHFS drug classes will be addressed by the clinical contractor or Medicaid after the clinical review of the class.

*Continued on next page*